$GRFS

Grifols ADR (GRFS) reported Q3 EPS of $0.32, beating estimates by $0.02, with revenue of $2.29B, exceeding expectations of $2.21B. The stock is up 8.68% over 3 months but down 7.70% over 12 months. InvestingPro rates its financial health as 'great performance'.

Grifols (GRFS) reported Q3 2026 revenue of €2.04B, up 8.4% at constant currency, with adjusted EBITDA of €538M and margins expanding to 26.4%. Leverage fell to 3.98x, and the company declared an interim dividend of €0.15 per share. Biopharma revenue grew 10.3%, driven by immunoglobulin demand, while albumin revenues declined 13.2% due to China market pressures. The stock rose 5% to $8.52 post-results.

Grifols, a Spanish pharmaceutical company, halted plasma collection in Canada indefinitely after Health Canada found deficiencies at its sites and two donor deaths. Health Canada later suspended Grifols' Winnipeg site license. Grifols' partnership with Canadian Blood Services (CBS) has been controversial due to its payment of donors, a practice new to Canada and reminiscent of past tainted blood scandals.

Health Canada cited Grifols' Calgary plasma clinic for accepting ineligible donors, mislabeling, and maintenance issues. The clinic allowed a donor to donate 16 times without verifying eligibility. Grifols temporarily shut down its 16 Canadian clinics following two donor deaths in Winnipeg. Health Canada found 10 areas of non-compliance, including insufficient staff training and poor record-keeping.

Spain’s Ibex 35 closed nearly flat, down 0.01% to 20,173, holding above 20,000 amid cautious trading. Moves were tied to Middle East geopolitical uncertainty and Strait of Hormuz concerns, lifting oil with Brent near $86. ArcelorMittal, Repsol and Indra rose; Aena, Grifols and Cellnex fell. Técnicas Reunidas faced pressure over potential €418m guarantees by Bapco. Sentix eurozone confidence improved.

Grifols (GRFS) reported first-half 2026 revenue of €3.574 billion, up 2.6% at constant currency, driven by BioPharma and IG franchise growth. Q2 adjusted EBITDA was €472 million (25.2% margin) and H1 free cash flow was €91 million. Full-year FCF guidance of $500 million to $575 million was maintained, with net leverage slightly below 4.2x. The company plans to expand ex-U.S. plasma sourcing (Egypt, Canada) and is evaluating a potential IPO of its U.S. Biopharma business.

Grifols S.A. (GRFS) reported first-half 2026 profit up 29%, citing growth in its Biopharma business, and reaffirmed its full-year outlook for 2026, according to the company.

Grifols will reorganize into a dual operating model, separating its US plasma business from the rest of its global structure. The company says US-sourced plasma will mainly serve the US market, while non-US plasma will supply Europe and other regions to reduce reliance on higher-cost US plasma. Biopharma US will be led by Felipe Palacios; ROW by Thierry Heinrich; president Roland Wandeler leaves 30 Sept.

Grifols (GRFS) is scheduled to release its Q1 2026 earnings on Thursday, April 30th, with analysts projecting $0.1731 EPS and $2.1247 billion in revenue. The company's earnings call is set for May 11, 2026. Institutional investors have significantly increased their stakes in Grifols, while Wall Street analysts have a mixed view, with an average "Reduce" rating and a $10.00 consensus price target.

Grifols (GRFS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.